Predicting Patterns of Long-Term CD4 Reconstitution in HIV-Infected Children Starting Antiretroviral Therapy in Sub-Saharan Africa: A Cohort-Based Modelling Study

PLoS Medicine

Volumn 10, Issue 10, 2013, Pages

  Picat, Marie Quitterie ^a,b,c   Lewis, Joanna ^a   Musiime, Victor ^d   Prendergast, Andrew ^e,f   Nathoo, Kusum ^g   Kekitiinwa, Addy ^h   Nahirya Ntege, Patricia ⁱ   Gibb, Diana M ^e   Thiebaut, Rodolphe ^b,c   Walker, A Sarah ^e   Klein, Nigel ^a   Callard, Robin ^a   Munderi, P ^j   Nahirya Ntege, P ^j   Katuramu, R ^j   Matama, L ^j   Nankya, F ^j   Nabulime, G ^j   Ruberantwari, A ^j   Sebukyu, R ^j   Tushabe, G ^j   Nakitto Kesi, D ^j   Mugyenyi, P ^d   Musiime, V ^d   Keishanyu, R ^d   Afayo, V D ^d   Bwomezi, J ^d   Byaruhanga, J ^d   Erimu, P ^d   Karungi, C ^d   Kizito, H ^d   Namala, W S ^d   Namusanje, J ^d   Nandugwa, R ^d   Najjuko, T K ^d   Natukunda, E ^d   Ndigendawani, M ^d   Nsiyona, S O ^d   Robinah, K ^d   Bainomuhwezi, B ^d   Sseremba, D ^d   Tezikyabbiri, J ^d   Tumusiime, C S ^d   Balaba, A ^d   Mugumya, A ^d   Nathoo, K J ^g   Bwakura Dangarembizi, M F ^g   Chidziva, E ^g   Mhute, T ^g   Vhembo, T ^g   Mandidewa, R ^g   Nyoni, D ^g   Tinago, G C ^g   Bhiri, J ^g   Muchabaiwa, D ^g   Phiri, M ^g   Masore, V ^g   Marozva, C C ^g   Maturure, S J ^g   Tsikirayi, S ^g   Munetsi, L ^g   Rashirai, K M ^g   Steamer, J ^g   Nhema, R ^g   Bikwa, W ^g   Tambawoga, B ^g   Mufuka, E ^g   Kekitiinwa, A ^k   Musoke, P ^k   Bakeera Kitaka, S ^k   Namuddu, R ^k   Kasirye, P ^k   Babirye, A ^k   Asello, J ^k   Nakalanzi, S ^k   Ssemambo, N C ^k   Nakafeero, J ^k   Tikabibamu, J ^k   Musoba, G ^k   Ssanyu, J ^k   Kisekka, M ^k   Gibb, D M ^e   Thomason, M J ^e   Walker, A S ^e   Cook, A D ^e   Naidoo, B ^e   Spyer, M J ^e   Male, C ^e   Glabay, A J ^e   Kendall, L K ^e   Prendergast, A ^e   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^e MRC CLINICAL TRIALS UNIT   (United Kingdom)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^h Paediatric Infectious Diseases Centre   (Uganda)

ⁱ UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^j MEDICAL RESEARCH COUNCIL   (United Kingdom)

^k MULAGO HOSPITAL   (Uganda)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; EFAVIRENZ; NEVIRAPINE; UREA; ZIDOVUDINE;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; AGE; ARTICLE; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHILD; CONTROLLED STUDY; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIRUS LOAD;

ADOLESCENT; AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE;

EID: 84886623702     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001542     Document Type: Article

References (40)

1. Joint United Nations Programme on HIV/AIDS (2012) UNAIDS report on the global AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS.
2. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ, (2008) Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 8: 477-489.
3. World Health Organization (2010) Antiretroviral therapy of HIV infection in infants and children: towards universal access: recommendations for a public health approach-2010 revision. Geneva: World Health Organization.
4. Sauvageot D, Schaefer M, Olson D, Pujades-Rodriguez M, O'Brien DP, (2010) Antiretroviral Therapy Outcomes in Resource-Limited Settings for HIV-Infected Children 5 Years of Age. Pediatrics 125: e1039-e1047.
5. de Beaudrap P, Rouet F, Fassinou P, Kouakoussui A, Mercier S, et al. (2008) CD4 cell response before and after HAART initiation according to viral load and growth indicators in HIV-1-infected children in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 49: 70-76.
6. Rouet F, Fassinou P, Inwoley A, Anaky M-F, Kouakoussui A, et al. (2006) Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS 20: 2315-2319.
7. Kariyo PC, Mbuzenakamwe MJ, Baramperanye E, Barutwanayo L, Nyatanyi J, et al. (2006) Antiretroviral therapy in a hundred Burundian children with AIDS [abstract]. Abstract number MOPE0208. AIDS 2006-XVI International AIDS Conference; 13-18 Aug 2006; Toronto, Ontario, Canada.
8. Anabwani GM, Lowenthal MM, Jibril HB, Sechele M, Schwarzwald H, et al. (2006) Long term response to highly active antiretroviral therapy among treatment naïve children in Botswana [abstract]. Abstract number MOPE0261. AIDS 2006-XVI International AIDS Conference; 13-18 Aug 2006; Toronto, Ontario, Canada.
9. DART Trial Team (2010) Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375: 123-31.
10. Achhra AC, Phanuphak P, Amin J, (2011) Long-term immunological outcomes in treated HIV-infected individuals in high-income and low-middle income countries. Curr Opin HIV AIDS 6: 258-265.
11. Gibb DM, Newberry A, Klein N, De Rossi A, Grosch-Woerner I, et al. (2000) Immune repopulation after HAART in previously untreated HIV-1-infected children. Lancet 355: 1331-1332.
12. Resino S, Seoane E, Pérez A, Ruiz-Mateos E, Leal M, et al. (2006) Different profiles of immune reconstitution in children and adults with HIV-infection after highly active antiretroviral therapy. BMC Infect Dis 6: 112.
13. Sleasman JW, Nelson RP, Goodenow MM, Wilfret D, Hutson A, et al. (1999) Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. J Pediatr 134: 597-606.
14. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group (2008) Sabin CA, Smith CJ, d'Arminio Monforte A, Battegay M, et al. (2008) Response to combination antiretroviral therapy: variation by age. AIDS 22: 1463-1473.
15. Bains I, Thiebaut R, Yates AJ, Callard R, (2009) Quantifying thymic export: combining models of naive T cell proliferation and TCR excision circle dynamics gives an explicit measure of thymic output. J Immunol 183: 4329-4336.
16. De Rossi A, Walker AS, Klein N, Forni DD, King D, et al. (2002) Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis 186: 312-320.
17. Steinmann GG, Klaus B, Muller-Hermelink H-K, (1985) The involution of the ageing human thymic epithelium is independent of puberty. Scand J Immunol 22: 563-575.
18. Thiebaut R, Jacqmin-Gadda H, Walker S, Sabin C, Prins M, et al. (2006) Determinants of response to first HAART regimen in antiretroviral-naive patients with an estimated time since HIV seroconversion. HIV Med 7: 1-9.
19. Lewis J, Walker AS, Castro H, De Rossi A, Gibb DM, et al. (2012) Age and CD4 count at initiation of antiretroviral therapy in HIV-infected children: effects on long-term T-cell reconstitution. J Infect Dis 205: 548-556.
20. ARROW Trial Team (2013) Kekitiinwa A, Cook A, Nathoo K, Mugyenyi P, et al. (2013) ARROW: a 5-year randomised factorial trial of routine vs clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in HIV-infected African children. Lancet 381: 1391-1403.
21. National Institutes of Health Division of AIDS (2009) Division of AIDS table for grading the severity of adverse events, version 1.0, December, 2004; clarification August 2009. Available: http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf. Accessed 24 September 2013.
22. Hulstaert F, Hannet I, Deneys V, Munhyeshuli V, Reichert T, et al. (1994) Age-related changes in human blood lymphocyte subpopulations. Clin Immunol Immunopathol 70: 152-158.
23. Huenecke S, Behl M, Fadler C, Zimmermann SY, Bochennek K, et al. (2008) Age-matched lymphocyte subpopulation reference values in childhood and adolescence: application of exponential regression analysis. Eur J Haematol 80: 532-539.
24. Wade AM, Ades AE, (1994) Age related reference ranges: significance tests for models and confidence intervals for centiles. Stat Med 13: 2359-2367.
25. Patel K, Hernan MA, Williams PL, Seeger JD, McIntosh K, et al. (2008) Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis 46: 1751-1760.
26. Resino S, Correa R, Bellon JM, Sanchez-Ramon S, Muñoz-Fernández MÁ, (2002) Characterizing immune reconstitution after long-term highly active antiretroviral therapy in pediatric AIDS. AIDS Res Hum Retroviruses 18: 1395-1406.
27. HIV Paediatric Prognostic Markers Collaborative Study (2010) Boyd K, Dunn DT, Castro H, Gibb DM, et al. (2010) Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children. AIDS 24: 1213-1217.
28. Cole TJ, Freeman JV, Preece MA, (1998) British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med 17: 407-429.
29. R Development Core Team (2011) R: a language and environment for statistical computing [computer program]. Vienna: R Foundation for Statistical Computing.
30. Pinheiro J, Bates D, DebRoy S, Sarkar D, R Development Core Team (2011) nlme: linear and nonlinear mixed effects models. Vienna: R Foundation for Statistical Computing.
31. Wolfram Research (2008) Mathematica 7.0 [computer program]. Champaign (Illinois): Wolfram Research.
32. Pakker NG, Notermans DW, de Boer RJ, Roos MTL, de Wolf F, et al. (1998) Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 4: 208-214.
33. Walker AS, Doerholt K, Sharland M, Gibb DM, (2004) for the Collaborative HIV Paediatric Study (CHIPS) Steering Committee (2004) Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS 18: 1915-1924.
34. van Rossum AMC, Scherpbier HJ, van Lochem EG, Pakker NG, Slieker WAT, et al. (2001) Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status. AIDS 15: 2267-2275.
35. Hainaut M, Ducarme M, Schandene L, Peltier CA, Marissens D, et al. (2003) Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 22: 62-69.
36. The Antiretroviral Therapy Cohort Collaboration (ART-CC) (2009) Lanoy E, May M, Mocroft A, Phillip A, et al. (2009) Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS 23: 2199-2208.
37. Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, et al. (2010) Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV Outpatient Study. Clin Infect Dis 51: 435-447.
38. Triant VA, Regan S, Lee H, Sax PE, Meigs JB, et al. (2010) Association of immunologic and virologic factors with myocardial infarction rates in a U.S. health care system. J Acquir Immune Defic Syndr 55: 615-619.
39. Guiguet M, Boué F, Cadranel J, Lang J-M, Rosenthal E, et al. (2009) Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 10: 1152-1159.
40. Thiebaut R, Jacqmin-Gadda H, Leport C, Katlama C, Costagliola D, et al. (2003) Bivariate longitudinal model for the analysis of the evolution of HIV RNA and CD4 cell count in HIV infection taking into account left censoring of HIV RNA measures. J Biopharm Stat 13: 271-282.